Johnson & Johnson has 58 disclosed EU lobbying meetings from 2024-07-16 to 2026-06-01: 15 with the European Commission and 43 with Members of the European Parliament. Source: EU Transparency Register no. 75617941310-89, Commission disclosures and MEP declarations. Methodology
Johnson & Johnson
EU lobbying footprint — who they meet, and on what.
- Register no.
- 75617941310-89 ↗
- Disclosed meetings
- 58 (15 Commission · 43 MEP)
- Period
- 2024-07-16 → 2026-06-01
Declared fields of interest: Business and industry · Climate action · Competition · Customs · Digital economy and society · Economy, finance and the euro · Employment and social affairs · Environment · Humanitarian aid and civil protection · Institutional affairs · International co-operation and development · Public health
Lobbying profile
as declared 2026-02-25- Category
- Companies & groups
- Legal status
- Corporation
- Declared lobbying cost
- €900,000
- Lobbying FTEs
- 6.25
- Members
- 4
At a glance
- Technology6
- Health3
- Trade1
- Chiara Galiffa3
- Mirzha De Manuel1
- Ioana Diaconescu1
- Ulla Schwager1
- Patricia Reilly1
Disclosed meetings
Newest first. EC = European Commission, EP = Member of the European Parliament.
- Introduction, exchange of views on Biotech Actsource ↗
- EU Biotech Actsource ↗
- Biotech Actsource ↗
- SANT COMMITTEE ONGOING WORKsource ↗
- 2026-05-07ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičLatest developments in EU-US relationssource ↗
- FP10source ↗
- Dispositifs médicauxsource ↗
- MDR Revisionsource ↗
- Health Policysource ↗
- Biotech Actsource ↗
- Biotech Actsource ↗
- Biotech Act Isource ↗
- 2026-02-03ECMirzha De Manuel · Cabinet of Commissioner Valdis DombrovskisImplementation of the EU pay transparency directivesource ↗
- Trade relations and business challengessource ↗
- 2026-01-16ECIoana Diaconescu · Head of UnitJohnson & Johnson requested this meeting to engage with DG TAXUD regarding the simplification agenda in the field of direct taxation.source ↗
- Health policysource ↗
- Pharmasource ↗
- 2025-12-03ECUlla Schwager · Head of UnitExchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sectorsource ↗
- 2025-12-01ECPatricia Reilly · Cabinet of President Ursula von der LeyenCompetitiveness and sustainable healthcaresource ↗
- 2025-12-01ECJana Dabbelt · Cabinet of Commissioner Olivér VárhelyiDigital and AI as an enabler in healthcaresource ↗
- 2025-10-28ECAdam Romanowski · Cabinet of Commissioner Maroš ŠefčovičPriorities of the EU’s trade agendasource ↗
- 2025-10-17ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičEU – US relationssource ↗
- 2025-09-25ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičEU – US relationssource ↗
- Critical Medicines Act and other prioritiessource ↗
- Presentation of Position on the Critical Medicines Actsource ↗
- Critical Medicines Act / address the root causes of medicine shortages while strengthening Europe’s life sciences ecosystem and competitivenesssource ↗
- Critical Medicines Actsource ↗
- Industrial Policysource ↗
- Critical Medicines Actsource ↗
- tematiche sanitariesource ↗
- Critical Medicines Actsource ↗
- Ongoing Legislationsource ↗
- CMAsource ↗
- Health policysource ↗
- Critical Medicinessource ↗
- Critical medicines actsource ↗
- Meeting regarding Critical Medicines Actsource ↗
- Critical Medicines Actsource ↗
- Health Policysource ↗
- Critical Medicines Actsource ↗
- 2025-06-03ECKilian Gross · Head of UnitExchange of views on application of the AI Act to the healthcare sector.source ↗
- Secteur des technologies medicalessource ↗
- 2025-04-04ECTobias Wiesenthal · Head of UnitScientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovationsource ↗
- 2025-04-04ECMaurice Whelan · Head of UnitScientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovationsource ↗
- EU pharmaceutical packagesource ↗
- 2025-03-25ECRoberto Viola · Director-GeneralDiscussion on Artificial Intelligence (AI), MedTech technologies and digital healthsource ↗
- 2025-03-25ECSaila Rinne · Head of UnitDiscussion on Artificial Intelligence (AI), MedTech technologies and digital healthsource ↗
- 2025-03-20ECGiulia Del Brenna · Head of UnitJ&J requested the meeting to address issues related to the recent adoption of the Commission proposal for a Critical Medicines Act (CMA) and other activities envisaged by the Commission which are deemed relevant to the pharmaceutical industry.source ↗
- Pharmaceutical strategysource ↗
- Priorities for the new legislative term 2024-2029source ↗
- Pharmaceutical industry - site visitsource ↗
- EU Health Policysource ↗
- Health policysource ↗
- Introductory Meetingsource ↗
- European Health policysource ↗
- European health and environmental policysource ↗
- Introductory Meetingsource ↗
- Introductory meeting at networking eventsource ↗
Lobbying in these areas
Frequently asked
How many EU lobbying meetings has Johnson & Johnson disclosed?
Johnson & Johnson (EU Transparency Register no. 75617941310-89) appears in 58 disclosed meetings with EU officials and MEPs between 2024-07-16 and 2026-06-01: 15 with the European Commission and 43 with Members of the European Parliament.
What does Johnson & Johnson lobby on?
Johnson & Johnson's disclosed EU meetings most often concern Technology, Health, Trade. Every meeting and its topic is listed with its official source on this page.
Who does Johnson & Johnson meet in Brussels?
Across its disclosed meetings, Johnson & Johnson has met Commission officials including Chiara Galiffa, Mirzha De Manuel, Ioana Diaconescu, and MEPs including CASTILLO Laurent, SOKOL Tomislav, ANDRIUKAITIS Vytenis Povilas. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
- EU Transparency Register profile (no. 75617941310-89) ↗
- European Commission meeting disclosures ↗
- European Parliament — MEP meeting declarations ↗
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.